Antibody-Drug Conjugates (ADCs) in oncology market Research Report

Antibody-Drug Conjugates (ADCs) in oncology Market Analysis

The Antibody-Drug Conjugates (ADCs) in oncology market refers to a class of targeted cancer therapies that combine monoclonal antibodies with potent cytotoxic agents. These agents are designed to selectively deliver the cytotoxic drug to cancer cells, minimizing damage to healthy cells. ADCs offer high specificity and improved therapeutic outcomes, representing a paradigm shift in cancer treatment.

Disruptive Impact and Opportunities:

ADCs are transforming oncology treatment paradigms by offering precision therapies that are both targeted and effective. Their ability to deliver cytotoxic agents directly to tumor cells without affecting surrounding healthy tissues presents significant opportunities in terms of improving patient outcomes and reducing adverse side effects. ADCs also provide new treatment options in cancers that were previously hard to treat. The market potential is considerable, with a focus on new, safe, easy-to-administer therapies that promise substantial efficacy. ADCs are poised to address unmet needs across a range of cancers, from breast and lung cancers to lymphomas and hematological malignancies.

Antibody-Drug Conjugates (ADCs) in oncology Market Segmentation - Emerging Drugs

• Teliso-V

• Telisotuzumab vedotin

• NBE-002

• Ladiratuzumab Vedotin

Antibody-Drug Conjugates (ADCs) in oncology Market Segmentation - Marketed Drugs

• Disitamab vedotin (RC48) + PD1

• SHR-A1811 + pyrotinib maleate

• ARX788 + pyrotinib maleate

• Zynlonta

Key Companies:

• Seagen

• AstraZeneca

• Daiichi Sankyo

• Merck

• RemeGen

• Jiangsu-Hengrui Medicine

• Zhejiang Medicine/NovoCodex

• NBE-Therapeutics

• ImmunoGen Inc.

Antibody-Drug Conjugates (ADCs) in oncology Market Segmentation - By Type

·  Monoclonal Antibodies (mAbs)

• HER2-targeted ADCs

• CD30-targeted ADCs

• CD33-targeted ADCs

• Other mAb-targeted ADCs

·  Linker Technology

• Cleavable Linkers

• Non-Cleavable Linkers

·  Payloads (Cytotoxic Drugs)

• Maytansinoid-based Payloads

• Auristatin-based Payloads

• Calicheamicin-based Payloads

• Duocarmycin-based Payloads

• Other Cytotoxic Agents

Antibody-Drug Conjugates (ADCs) in oncology Market Segmentation - By Administration Type

·  Intravenous (IV) Administration

• Standard Infusion

• Extended Infusion

·  Subcutaneous (SC) Administration

·  Oral Administration

What’s in It for You?

• Gain insights into emerging ADC therapies poised to disrupt oncology treatment landscapes.

• Understand competitive dynamics with a detailed overview of key players and their strategies.

• Identify market opportunities based on emerging drugs and evolving treatment paradigms.

• Anticipate market trends and plan for future investment and R&D directions.

• Access a comprehensive analysis of drug candidates currently in development and their market potential.